Herbert Loong Announced as Candidate for ASCO Nominating Committee

Herbert Loong Announced as Candidate for ASCO Nominating Committee

Herbert Loong, MBBS, FRCP, FASCO, Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong, has been announced as a candidate for the American Society of Clinical Oncology (ASCO) Nominating Committee in the Undesignated Member category.

The election includes two available seats, each carrying a three-year term.

With a professional background spanning clinical oncology, early-phase clinical trials, international collaboration, and medical education, Dr. Loong brings experience in both academic cancer medicine and professional oncology leadership.

His previous service as Chair of ASCO’s International Affairs Committee, together with his involvement in the Education Council, Annual Meeting Scientific Program Committee, and Breakthrough Program Committee, reflects his contributions to the Society’s international and educational activities.

Advancing Clinical Oncology in Hong Kong

Dr. Loong currently serves as Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong.

He also holds a conjoint appointment as Honorary Consultant in the Department of Clinical Oncology at Prince of Wales Hospital, within the Hospital Authority Hong Kong.

These positions connect academic medicine with clinical oncology practice, allowing engagement across medical education, cancer treatment, and institutional clinical activities.

Hong Kong’s academic medical institutions play an important role in cancer research and clinical education in the Asia-Pacific region, where international collaboration and access to emerging therapies remain significant priorities.

Dr. Loong’s appointments place him within this academic and clinical environment, combining university responsibilities with a hospital-based consultant role.

His professional activities also extend into clinical trial development, an area that continues to influence the introduction of new cancer treatments.

At the Forefront of Early-Phase Cancer Research

In addition to his academic and clinical appointments, Dr. Loong serves as Medical Director (Oncology) of the Phase 1 Clinical Trial Centre at The Chinese University of Hong Kong.

Early-phase clinical trials represent a critical stage in the development of new anticancer therapies.

Phase 1 studies generally focus on evaluating the safety, tolerability, appropriate dosing, and preliminary activity of investigational treatments.

These trials provide an important foundation for subsequent clinical research and may offer eligible patients opportunities to participate in studies of emerging therapeutic approaches.

As oncology treatment becomes increasingly informed by molecular biology and precision medicine, early-phase research continues to evolve, incorporating novel targeted therapies, immunotherapies, and other investigational strategies.

Dr. Loong’s leadership role at the Phase 1 Clinical Trial Centre connects his professional responsibilities with this important area of cancer drug development.

Strengthening ASCO’s International Engagement

A notable component of Dr. Loong’s service to ASCO has been his role as Chair of the International Affairs Committee.

ASCO’s international activities support professional collaboration, oncology education, and engagement with cancer care communities across different regions of the world.

The International Affairs Committee contributes to discussions and initiatives concerning the Society’s global activities and relationships with oncology professionals outside the United States.

Dr. Loong’s previous leadership of the committee reflects his involvement in ASCO’s international priorities.

His professional background in Hong Kong also provides experience within an oncology environment shaped by regional healthcare systems, academic partnerships, and international scientific exchange.

As cancer care continues to develop globally, collaboration between oncology organizations and institutions remains important for sharing scientific knowledge, supporting professional education, and addressing differences in access to care.

Contributing to Oncology Education and Scientific Programming

Dr. Loong has also served as a member of ASCO’s Education Council and Annual Meeting Scientific Program Committee.

The Education Council contributes to the Society’s broader educational activities, supporting opportunities for oncology professionals to maintain and expand their knowledge throughout their careers.

His involvement in the Annual Meeting Scientific Program Committee connected him with the scientific programming of one of the world’s largest oncology conferences.

The ASCO Annual Meeting provides an international platform for presenting clinical research findings, discussing emerging treatment strategies, and examining developments across cancer specialties.

Participation in these committees reflects engagement with both the scientific and educational aspects of oncology.

Dr. Loong’s service demonstrates involvement in activities that help connect research developments with the professional learning needs of clinicians and researchers.

Supporting New Directions in Cancer Research

Another component of Dr. Loong’s ASCO volunteer work has been his membership on the Breakthrough Program Committee.

The ASCO Breakthrough program provides a platform for discussing advances in oncology research, innovative treatment approaches, and emerging scientific developments.

Its focus on innovation reflects the rapid changes taking place across cancer medicine, particularly in areas such as precision oncology, novel therapeutics, and clinical research.

Dr. Loong’s participation in the committee connects his professional experience in early-phase clinical trials with ASCO’s activities focused on scientific innovation.

His involvement across the International Affairs Committee, Education Council, Scientific Program Committee, and Breakthrough Program Committee demonstrates experience in several areas of the Society’s work.

The Role of the ASCO Nominating Committee

The ASCO Nominating Committee plays an important role in the Society’s governance by participating in the identification and evaluation of candidates for ASCO leadership positions.

Its responsibilities contribute to the process through which future leaders are considered for service within the organization.

The Undesignated Member category provides an opportunity for oncology professionals from different specialties and professional backgrounds to participate in this work.

For the upcoming election, two seats are available, each carrying a three-year term.

Dr. Loong’s candidacy brings together experience in clinical oncology, academic medicine, early-phase research, international engagement, and professional education.

His previous leadership and committee appointments within ASCO provide a background relevant to the responsibilities of the Nominating Committee.

A New Chapter in ASCO Leadership

Dr. Herbert Loong’s candidacy for the ASCO Nominating Committee represents a potential extension of his longstanding involvement with the Society.

From his academic and clinical responsibilities at The Chinese University of Hong Kong and Prince of Wales Hospital to his leadership of the Phase 1 Clinical Trial Centre, his professional work spans several aspects of contemporary oncology.

His previous service as Chair of the ASCO International Affairs Committee, along with his participation in the Education Council, Annual Meeting Scientific Program Committee, and Breakthrough Program Committee, reflects his engagement with the Society’s international, scientific, and educational activities.

If elected, Dr. Loong would serve a three-year term on the ASCO Nominating Committee, contributing to the process of identifying and evaluating future leaders of the organization.

The election will determine the two representatives selected for the Undesignated Member seats as ASCO prepares for its upcoming leadership cycle.

Discover more articles like this on OncoDaily.

Vahe Grigoryan
Fact checked by Vahe Grigoryan MD, Editorial Director
Vahe Grigoryan
Medically reviewed by Vahe Grigoryan MD, Editorial Director